Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). .